Metrics as of 10/15/2026, 08:10 AM (Berlin time), refresh in progress.
Black Diamond Therapeutics Stock
Black Diamond Therapeutics, Inc.
Company data
- Sector
- Healthcare
- Industry
- Biotechnology
- Country
- United States
- CEO
- Mark A. Velleca
- Employees
- 21
- Market cap
- $97 M
- IPO
- 31/01/2020
Black Diamond Therapeutics, Inc. is a biotechnology enterprise dedicated to discovering, advancing, and bringing to market therapeutic agents specifically designed for patients with genetically characterized tumors. A core part of its pipeline is BDTX-189, an irreversible small molecule inhibitor. This compound is…
Black Diamond Therapeutics stock: price history
1D
+1.2%
1W
-7.1%
1M
-16.3%
6M
-40.8%
YTD
-30.0%
1Y
-54.8%
2Y
-51.1%
5Y
-79.2%
10Y
–
Next earnings date
Next earnings date
05/11/2026 (in 19 days)
Volatility around earnings
~11% weaker price swings than usual
Ask the agents about Black Diamond Therapeutics
Analyst assessment of Black Diamond Therapeutics
PRICE TARGET LOW
US$8.00
CONSENSUS
US$11.83
MEDIAN
US$9.50
PRICE TARGET HIGH
US$20.00
0
STRONG BUY
10
BUY
1
HOLD
0
SELL
0
STRONG SELL
11
TOTAL · Buy
As of: 29/04/2026
Black Diamond Therapeutics stock metrics
P/E
-2.3
P/B
1.01
EV/EBITDA
-2.33
RETURN ON EQUITY
-10.3%
NET MARGIN
0.0%
DEBT/EQUITY
0.18
DIVIDEND YIELD
0.0%
AS OF
30/06/2026
Free float & liquidity
FREE FLOAT
80.5%
FLOAT SHARES
46,154,855
AVG. DAILY VOLUME (30D)
617,743
Insider transactions (SEC)
Behbahani Ali
Raman Prakash
Behbahani Ali
Raman Prakash
Institutional holders
Comparable stocks
Frequently asked questions about Black Diamond Therapeutics stock
What does Black Diamond Therapeutics do?
Black Diamond Therapeutics, Inc. is a company in the Healthcare sector, Biotechnology industry, headquartered in United States.
The CEO is Mark A. Velleca, the company employs around 21 people.
The IPO was on 31/01/2020; the stock trades on NASDAQ under the ticker BDTX.
What do analysts say about Black Diamond Therapeutics stock?
11 analysts rate the stock, the consensus is Buy (as of 29/04/2026).
The average price target is US$11.83, ranging from US$8.00 to US$20.00, with a median of US$9.50.
This is an external assessment, not a statement by Market Jury.
When does Black Diamond Therapeutics report next?
The next earnings date is 05/11/2026.
Around past earnings, price swings were roughly -11% stronger than usual.
Does Black Diamond Therapeutics pay a dividend?
No, Black Diamond Therapeutics currently does not pay a dividend.
Which stocks are comparable to Black Diamond Therapeutics?
Comparable stocks include Vertex Pharmaceuticals, Moderna, Regeneron Pharmaceuticals, Revolution Medicines, Incyte, Exelixis, Neurocrine Biosciences and Summit Therapeutics.
How can I get Black Diamond Therapeutics stock analyzed?
Clicking "Analyze stock" lets five strategies assess Black Diamond Therapeutics against fixed, published rules and judge it bullish, neutral or bearish. The jury states where it disagrees. A free account starts with 5 credits, a quick check costs 1 credit, a full analysis 2 credits.
Not investment advice. Past performance is not an indicator of future results.